Review Article

An Analysis of Safety Profiles of Treatments for Diarrhoea-predominant Irritable Bowel Syndrome

Brian E. Lacy


Aliment Pharmacol Ther. 2018;48(8):817-830. 

In This Article


A search of the Medline and Embase databases for articles available through 02 May 2018 was conducted to identify relevant English-language articles using the following key words: "irritable bowel syndrome," "diarrhoea-predominant irritable bowel syndrome," "IBS," "IBS-D," "dietary modification," "probiotic," "alosetron," "ondansetron," "loperamide," "Lomotil" (Lomotil®, G.D. Searle LLC, New York, NY, USA), "diphenoxylate and atropine," "eluxadoline," "rifaximin," "bile acid sequestrant," "antidepressant," "tricyclic antidepressant," "selective serotonin reuptake inhibitor," "complementary and alternative medicine," "complementary and alternative therapy," "CAM," "herbal," "Iberogast" (Iberogast, Bayer Consumer Care AG, Basel, Switzerland), "STW 5," "Tongxie Yaofang," "Tong Xie Yao Fang," "peppermint oil," "cognitive behavioral therapy," "hypnotherapy," "yoga," "acupuncture," "clinical trial," "adverse event," and "safety." Abstracts were reviewed for clinical studies that evaluated treatment safety, efficacy, or both in adults with IBS-D. Additional relevant publications were identified from article reference lists. If number needed to treat data were reported in >1 publication, then results from each publication were included.